Home » Topics » Vertex Pharmaceuticals

U.S. approves new drug for rare cystic fibrosis

WASHINGTON — US regulators on Tuesday approved Kalydeco, a new, gene-targeted drug treatment for people who have a rare kind of the incurable lung disease cystic fibrosis. Made by the Massachusetts-based Vertex Pharmaceuticals, Kalydeco (ivacaftor) was approved by the US Food and Drug Administration on a fast-track for drugs that…